Literature DB >> 29282366

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Daniella M Schwartz, Yuka Kanno, Alejandro Villarino, Michael Ward, Massimo Gadina, John J O'Shea.   

Abstract

This corrects the article DOI: 10.1038/nrd.2017.201.

Entities:  

Year:  2017        PMID： 29282366      PMCID： PMC6168198          DOI： 10.1038/nrd.2017.267

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  176 in total

1.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

2.  Tofacitinib Response in Juvenile Idiopathic Arthritis (JIA) and Collagenous Colitis.

Authors:  Bryon Tseng; Arash Amighi; Kara Bradford; Hanlin L Wang; Terri E Getzug; Ernest Brahn
Journal:  J Clin Rheumatol       Date:  2016-12       Impact factor: 3.517

3.  Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.

Authors:  Robert E Chapin; Douglas J Ball; Zaher A Radi; Steven W Kumpf; Petra H Koza-Taylor; David M Potter; W Mark Vogel
Journal:  Toxicol Sci       Date:  2016-10-05       Impact factor: 4.849

Review 4.  Molecular mechanisms of pruritus.

Authors:  J Meng; M Steinhoff
Journal:  Curr Res Transl Med       Date:  2016-11-04       Impact factor: 4.513

5.  Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.

Authors:  Shiao Hui Melissa Liew; Kelly K Nichols; Karen J Klamerus; Jim Z Li; Min Zhang; Gary N Foulks
Journal:  Ophthalmology       Date:  2012-04-22       Impact factor: 12.079

6.  Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.

Authors:  Jashin J Wu; Bruce E Strober; Peter R Hansen; Ole Ahlehoff; Alexander Egeberg; Abrar A Qureshi; Debbie Robertson; Hernan Valdez; Huaming Tan; Robert Wolk
Journal:  J Am Acad Dermatol       Date:  2016-08-04       Impact factor: 11.527

Review 7.  Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis.

Authors:  Alejandro Souto; Eva Salgado; José Ramón Maneiro; Antonio Mera; Loreto Carmona; Juan J Gómez-Reino
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

8.  Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.

Authors:  Philip G Conaghan; Mikkel Østergaard; Michael A Bowes; Chunying Wu; Thomas Fuerst; Désirée van der Heijde; Fedra Irazoque-Palazuelos; Oscar Soto-Raices; Pawel Hrycaj; Zhiyong Xie; Richard Zhang; Bradley T Wyman; John D Bradley; Koshika Soma; Bethanie Wilkinson
Journal:  Ann Rheum Dis       Date:  2016-01-25       Impact factor: 19.103

9.  Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.

Authors:  Tsutomu Takeuchi; Yoshiya Tanaka; Manabu Iwasaki; Hiroaki Ishikura; Satoshi Saeki; Yuichiro Kaneko
Journal:  Ann Rheum Dis       Date:  2015-12-15       Impact factor: 19.103

10.  Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.

Authors:  Maxime Dougados; Désirée van der Heijde; Ying-Chou Chen; Maria Greenwald; Edit Drescher; Jiajun Liu; Scott Beattie; Sarah Witt; Inmaculada de la Torre; Carol Gaich; Terence Rooney; Douglas Schlichting; Stephanie de Bono; Paul Emery
Journal:  Ann Rheum Dis       Date:  2016-09-29       Impact factor: 19.103
View more
  87 in total

Review 1.  Novel Immunomodulatory Approaches for Porcine Islet Xenotransplantation.

Authors:  So-Hee Hong; Hyun-Je Kim; Seong-Jun Kang; Chung-Gyu Park
Journal:  Curr Diab Rep       Date:  2021-01-12       Impact factor: 4.810

Review 2.  [Biologicals and small molecules for rheumatoid arthritis].

Authors:  Stephan Blüml
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372

Review 3.  IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.

Authors:  Hao Li; George C Tsokos
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-13       Impact factor: 8.667

Review 4.  Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects.

Authors:  Chiara Crotti; Elena Agape; Andrea Becciolini; Martina Biggioggero; Ennio Giulio Favalli
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

Review 5.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

6.  Inflammation Unrestrained by SIRPα Induces Secondary Hemophagocytic Lymphohistiocytosis Independent of IFN-γ.

Authors:  Koby Kidder; Zhen Bian; Lei Shi; Yuan Liu
Journal:  J Immunol       Date:  2020-10-07       Impact factor: 5.422

Review 7.  JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.

Authors:  Azucena Salas; Cristian Hernandez-Rocha; Marjolijn Duijvestein; William Faubion; Dermot McGovern; Severine Vermeire; Stefania Vetrano; Niels Vande Casteele
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-19       Impact factor: 46.802

8.  Development and utilization of human decidualization reporter cell line uncovers new modulators of female fertility.

Authors:  Meade Haller; Yan Yin; Liang Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-09       Impact factor: 11.205

Review 9.  JAK/STAT signaling in regulation of innate lymphoid cells: The gods before the guardians.

Authors:  Helena Stabile; Gianluca Scarno; Cinzia Fionda; Angela Gismondi; Angela Santoni; Massimo Gadina; Giuseppe Sciumè
Journal:  Immunol Rev       Date:  2018-11       Impact factor: 12.988

Review 10.  Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.

Authors:  Isabelle Amigues; Alexander H Pearlman; Aarat Patel; Pankti Reid; Philip C Robinson; Rashmi Sinha; Alfred Hj Kim; Taryn Youngstein; Arundathi Jayatilleke; Maximilian Konig
Journal:  Expert Rev Clin Immunol       Date:  2020-11-25       Impact factor: 4.473
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.